文献速递乳腺癌

Ⅲ期DESTINY-Breast03研究中接受德曲妥珠单抗或恩美曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者的患者报告结局与住院数据

Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
PubMed 文献 · Ann Oncol · 2023-05-12

在Ⅲ期DESTINY-Breast03试验中,对比德曲妥珠单抗(T-DXd)与恩美曲妥珠单抗(T-DM1)治疗HER2阳性转移性乳腺癌的患者报告结局与住院数据。T-DXd组(n=253)与T-DM1组(n=260)的EORTC QLQ-C30基线总体健康状况相似,治疗期间均无临床意义变化(较基线变化<10分)。T-DXd组住院18例(6.9%),T-DM1组19例(7.2%),中位至首次住院时间分别为219.5天与60.0天。

要点

  • T-DXd组与T-DM1组EORTC QLQ-C30基线总体健康状况相似,治疗期间均无临床意义变化(<10分)。
  • 所有预设PRO变量的至确定性恶化风险比在数值上偏向T-DXd而非T-DM1。
  • T-DXd组住院18例(6.9%)vs T-DM1组19例(7.2%),中位至首次住院时间219.5天 vs 60.0天。

核心结论

  • EORTC总体健康状况/生活质量在两种治疗期间均得以维持,尽管T-DXd治疗持续时间长于T-DM1,T-DXd组健康相关生活质量未恶化。
  • 所有预设感兴趣变量(包括疼痛)的至确定性恶化风险比在数值上偏向T-DXd而非T-DM1,提示T-DXd可能延迟健康相关生活质量恶化时间。
  • T-DXd组中位至首次住院时间为T-DM1组的三倍。
  • 结合已报告的疗效改善与可控毒性,这些结果支持T-DXd对HER2阳性转移性乳腺癌患者的总体获益。

研究设计与样本

  • Ⅲ期DESTINY-Breast03临床试验的患者报告结局与住院数据分析。
  • 评估预设PRO指标,包括EORTC QLQ-C30、EORTC QLQ-BR45及EQ-5D-5L视觉模拟量表。
  • 分析包括较基线变化、至确定性恶化时间(TDD)及住院相关终点。
  • T-DXd组n=253,T-DM1组n=260;中位治疗持续时间T-DXd为14.3个月,T-DM1为6.9个月。

主要发现

  • T-DXd组(n=253)与T-DM1组(n=260)EORTC QLQ-C30基线总体健康状况评分相似,治疗期间均无临床意义变化(较基线变化<10分)。
  • QLQ-C30总体健康状况(主要PRO变量)及所有其他预设PRO(QLQ-C30各亚量表、QLQ-BR45手臂症状量表、EQ-5D-5L视觉模拟量表)的TDD风险比在数值上偏向T-DXd而非T-DM1。
  • 全部随机患者中,T-DXd组18例(6.9%)vs T-DM1组19例(7.2%)住院。
  • 中位至首次住院时间T-DXd组219.5天 vs T-DM1组60.0天。

关键数值与推荐

  • 临床意义变化阈值定义为较基线变化<10分。
  • TDD分析覆盖QLQ-C30总体健康状况(主要PRO变量)及所有其他预设PRO变量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan (T-DXd) showed superior progression-free survival and overall survival versus trastuzumab emtansine (T-DM1) and manageable safety in patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer. Here, patient-reported outcomes (PROs) are reported along with hospitalization data. PATIENTS AND METHODS: Patients in DESTINY-Breast03 were assessed for prespecified PRO measures, including European Organization for Research and Treatment of Cancer quality of life (EORTC-QoL) questionnaires [the oncology-specific EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and breast cancer-specific EORTC QLQ-BR45] and the generic EuroQol 5-dimension 5-level questionnaire (EQ-5D-5L) visual analogue scale. Analyses included change from baseline, time to definitive deterioration (TDD), and hospitalization-related endpoints. RESULTS: EORTC QLQ-C30 baseline global health status (GHS) scores for T-DXd (n = 253) and T-DM1 (n = 260) were similar, with no clinically meaningful change (<10-point change from baseline) while on either treatment (median treatment duration: T-DXd, 14.3 months; T-DM1, 6.9 months). TDD analyses of QLQ-C30 GHS (primary PRO variable) and all other prespecified PROs (QLQ-C30 subscales, the QLQ-BR45 arm symptoms scale, and the EQ-5D-5L visual analogue scale) suggested T-DXd was numerically favored over T-DM1 based on TDD hazard ratios. Of all randomized patients, 18 (6.9%) receiving T-DXd versus 19 (7.2%) receiving T-DM1 were hospitalized, and the median time to first hospitalization was 219.5 versus 60.0 days, respectively. CONCLUSIONS: In DESTINY-Breast03, EORTC GHS/QoL was maintained on both therapies throughout treatment, indicating that despite the longer treatment duration with T-DXd versus T-DM1, health-related QoL did not worsen on T-DXd. Furthermore, TDD hazard ratios numerically favored T-DXd over T-DM1 in all prespecified variables of interest including pain, suggesting T-DXd may delay time until health-related QoL deterioration compared with T-DM1. Median time to first hospitalization was three times longer with T-DXd versus T-DM1. Together with reported improved efficacy and manageable toxicity, these results support the overall benefit of T-DXd for patients with HER2+ metastatic breast cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Curigliano G, Dunton K, Rosenlund M, et al. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Ann Oncol. 2023. PMID: 37179020. doi:10.1016/j.annonc.2023.04.516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。